Aberrant Expression of a Proliferation-Inducing Ligand Underlies Autoimmune Mechanisms in Immune Thrombocytopenia. (30th January 2021)

• Record Type: Journal Article
• Authors: Hao, Y. F.; Bi, H.; Li, H. Y.; Yin, L. M.; Yu, J. X.; Tao, W.; Mu, H. L.; Yang, R. C.; Zhou, Z. P.; Tai, W. L.
• Other Names: Ortega Enrique Academic Editor.
• Is Part Of: Journal of immunology research. Volume 2021(2021)
• Publication Date: 2021-01-30
• Subjects: Immunology -- Periodicals; Immunology -- Research -- Periodicals; 616.07905
• DOI: 10.1155/2021/3676942
• Languages: English
• ISSNs: 2314-8861

Abstract

Abstract : Purpose . To study the relationship between surface membrane-bound APRIL and ITP. Methods . The peripheral blood of all subjects, 50 patients diagnosed with ITP and 25 healthy controls, was collected. Flow cytometry was used to detect the expression of membrane-bound APRIL on immune cells and platelets. ELISA was used to detect the content of soluble APRIL in plasma. Results . Membrane-bound APRIL was only expressed on the surface of platelets in both ITP patients and controls. APRIL expression on the platelet surface was significantly lower in newly diagnosed (P < 0.001 ) and chronic (P < 0.001 ) ITP patients than in controls. Platelet surface APRIL level was significantly enhanced in patients with complete remission after treatment (P = 0.02 ) but not in those with no response after treatment. Platelet surface APRIL level in ITP patients was negatively correlated with serum APRIL level (r = − 0.09765, P = 0.0424 ). Conclusions . Platelet surface APRIL may play a key immunoregulative role. Platelet surface APRIL is likely to be one source of the excessive serum APRIL in ITP patients. The effectiveness of treatment may be measured by determining the platelet surface APRIL levels in ITP patients.